IMPROVING PATIENT
C A R E & P H A R M A C Y
P R O F I T A B I L I T Y
C O M M U N I T Y , S P E C I A L T Y , & L T C E D I T I O N
FALL 2024
20 Unique
Products &
Services
Wholesalers &
Distributors
Industry Expert Q&A, Market Leaders
Buyer’s Guide, and More pg. 48
DSCSA Update
What You Need to Know
About the Small Dispenser
Exemption and Other Waivers
or Exemptions pg. 68
SureCost Case Study
How HAC Pharmacies Leverage
Data-Driven Purchasing
Decisions to Save Thousands of
Dollars Every Month pg. 30
Miriam Cho, PharmD
President & Chief Pharmacy Officer
~ MACRx
Long-Term Care Pharmacies
The Role of Pharmacy
Management Software in
Selling a Pharmacy?
Highest Price,
Lowest Risk
Rely on Proven Guidance
from a Dedicated Professional
Nationwide Representation pharmacycbs.com
No conflict of interest, we do NOT pay for endorsements
Experienced: Dan has personally sold over 200 pharmacies
Licensed and insured broker, pharmacist, and former multi-pharmacy owner
A fiduciary who is focused on your best outcome
Utilizing nationwide competition from both chain and independent buyers
My only goal is to get you the best deal possible.
Competition and multiple ofers are key. Don't settle for one ofer!
Let me work towards your best possible outcome.
Daniel J. Lannon
RPh, Broker/Owner
Call: 888-808-4RPH (4774)
Call/Text: 651-769-4932
Email: dan@pharmacycbs.com
Call Today for a
FREE Consultation
Faster Credit
No Hidden Charges
Simplified Reimbursement
Credit due through the OneCheck
Select program is consolidated
into a single check.
Choose to receive your check
within 10, 30, or 90 days after
your return.
The fee is an all-inclusive
percentage of your returnable
product value.
Contact
Us
If you’re in need of a new returns provider,
Return Solutions is one of the oldest and
most trusted in the industry. With over 30
years of experience and a focus on
independent pharmacies and regional
chains, we put you first so you can focus
on your business and your patients.
The Independent’s
Choice for
Rx Returns
1.800.579.4804
www.drugreturns.com
support@drugreturns.com
Optimize your Rx returns
process and payment.
Return Solutions offers the
fastest credit in the industry.
Sign up today to receive
a special promotion on
your first return!
On-Site service is completely turnkey
Mail-In service is easy and economical
Fastest payment as quickly as 10 days
No additional charges
Contents
page 17
Stat Temp®
From Health
Care Logistics®
Transforms
Temperature
Monitoring
Ensure temperature accuracy
throughout the healthcare
setting with this fully
customizable web-based system
that installs without equipment
and without a subscription.
McKesson’s BlistMED
Revolutionizes
Multi-Dose Blister
Packaging in Retail
Pharmacy
Improve medication management
and employee satisfaction
with BlistMED, an advanced
multi-dose blister packaging
robot that enhances efficiency,
accuracy, and patient safety,
all in a small footprint.
®
page 19
GX Solutions Cold Storage
Safe for Use in Clean Room Environments
HELMER’S EXCLUSIVE OPTICOOL™
TECHNOLOGY FEATURED ON GX SOLUTIONS
MEDICAL-GRADE REFRIGERATORS AND FREEZERS
SUPPORTS TEMPERATURE UNIFORMITY
GX Solutions are the first cold-storage solutions to offer optimized
control in three key temperature management areas: uniformity, stability,
and recovery.
SUPPORTS ENERGY EFFICIENCY AND SUSTAINABILITY
ENERGY STAR® certified and up to 50-65% more energy efficient than
conventional medical-grade cold storage with natural HC refrigerants
that decrease heat output, carbon footprint, and global warming
potential.
SUPPORTS CLEANROOM APPLICATIONS
GX Solutions have been tested and are safe for ISO 5 clean room
applications.
SUPPORTS RELIABILITY
Designed and built to ensure long-lasting reliability, limiting downtime
and interruption to workflow.
GX Solutions Pharmacy Refrigerators
Include NSF/ANSI 456 Certifcation and
ISO Class 5 Clean Room Compatibility
Learn More
© 2024 Helmer Inc. All rights reserved
Helmer GX
Solutions Safe for
Use in Clean Room
Environments ISO
Class 5 and Above
GX Solutions pharmacy
refrigerators include NSF/
ANSI 456 Certification and
ISO Class 5 clean room
compatibility.
page 21
FALL 2024 I RETAIL/COMMUNITY • SPECIALTY • LTC
Pharmacy
Pharmacy
Discover the stories, research,
and reports from real pharmacies.
Case Studies
Case Studies
Visit the library at RXinsider.com
Pharmacy Case
Studies
Discover the stories,
research, and reports from
real pharmacies.
page 22-23
You owe it to yourself to see what PharmaLink can provide. You could realize up
to thousands of dollars in annual return reimbursements value – and more money
to help run your business and realize better profitability.
Call us today for an easy, no obligation comparison at (800) 257-3527.
Hidden fees and murky
payment agreements are
designed to keep you in the
dark about what your real rate
is for the processing of your
returns. Quick pay rates are
often costing you 20% - 40%
of your return value!
HIGHER
RATES
Are you ever shown the exact
value of the manufacturer
credits received? PharmaLink
always provides you with
the ACTUAL value received
from the Manufacturer
– not an estimate.
TRANSPARENCY
ZERO
Overall value of your
returned products can be
deflated to cover shortages in
manufacturer disbursements
instead of using ACTUAL
manufacturer’s credit value
used by PharmaLink.
DEFLATED
ESTIMATES
Quick pay programs benefit returns companies, not YOU!
Your quick pay returns program
literally could be costing you thousands
© PharmaLink Inc. 0724
REVERSE DISTRIBUTION SERVICES
If you’re on a quick pay returns program, it’s likely coming at a big cost...
LEARN MORE
Simple to store.
Longer shelf life.
Treatment in the convenience
of a room temperature,
intramuscular injection.
INDICATIONS & USAGE1
LEUPROLIDE ACETATE INJECTION DEPOT (leuprolide acetate
for depot suspension) 22.5 mg for 3-month administration
(leuprolide acetate) is indicated for palliative treatment of
advanced prostate cancer.
IMPORTANT SAFETY INFORMATION1
Contraindications: Hypersensitivity: LEUPROLIDE ACETATE
INJECTION DEPOT is contraindicated in individuals with known
hypersensitivity to GnRH agonists or any of the excipients
in LEUPROLIDE ACETATE INJECTION DEPOT. Anaphylactic
reactions to GnRH agonists have been reported.
Warnings And Precautions:
x
Tumor Flare: LEUPROLIDE ACETATE INJECTION DEPOT
causes increases in serum levels of testosterone during
the first weeks of treatment. Isolated cases of ureteral
obstruction and spinal cord compression have been
observed, which may contribute to paralysis with or without
fatal complications. Transient worsening of symptoms may
develop. Patients may experience a temporary increase in
bone pain. Patients with metastatic vertebral lesions and/or
with urinary tract obstruction should be closely observed.
x
Hyperglycemia and Diabetes: Hyperglycemia and an
increased risk of developing diabetes have been reported in
men receiving GnRH agonists. Monitor blood glucose and/or
glycosylated hemoglobin (HbA1c) periodically
in patients receiving a GnRH.
x
Cardiovascular Diseases: Increased risk of developing
myocardial infarction, sudden cardiac death and stroke has
been reported, and should be evaluated carefully along with
cardiovascular risk factors. Patients receiving a GnRH agonist
should be monitored for symptoms and signs suggestive of
development of cardiovascular disease and be managed
accordingly.
x
Effect on QT/QTc Interval: Androgen deprivation therapy
may prolong the QT/QTc interval. Providers should consider
whether the benefits of androgen deprivation therapy
outweigh the potential risks in patients with congenital
long QT syndrome, congestive heart failure, frequent
electrolyte abnormalities, and in patients taking drugs
known to prolong the QT interval. Electrolyte abnormalities
should be corrected. Consider periodic monitoring of
electrocardiograms and electrolytes.
REFERENCES:
1. LEUPROLIDE PRESCRIBING INFORMATION, CIPLA, 2018.
2. Data on file. CIP-REF-LEU-001. Warren, NJ: Cipla USA; 2022
Medical Information:
Report Adverse Events/Side Effects | Report Product Complaints | Submit Medical Inquiries:
Contact Us: 1-866-604-3268 DrugSafety@cipla.com
Leuprolide Acetate
Injection Depot
(Leuprolide Acetate for Depot Suspension)
22.5 mg*
*Each syringe contains 22.5 mg
(provided as Leuprolide acetate)
WHOLESALER/DISTRIBUTOR ORDER ENTRY NUMBER
CENCORA
CARDINAL
MCKESSON
MORRIS & DICKSON
10274981
5815139
2655967
190595
To place your order, please contact your wholesaler.
Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059
Customer Service Tel.: 844-CIPLA US (844-247-5287)
Email: Cipla.CS@cipla.com
JUNE 2024 CUSAI-06212024-03
x
Convulsions: Convulsions have been observed and should
be managed accordingly.
x
Laboratory Tests: Monitor serum levels of testosterone
following injection of LEUPROLIDE ACETATE INJECTION
DEPOT 22.5 mg for 3-month administration.
x
Embryo-Fetal Toxicity: LEUPROLIDE ACETATE INJECTION
DEPOT may cause fetal harm when administered to a
pregnant woman. Advise pregnant patients and females
of reproductive potential of the potential risk to the fetus.
Most common adverse events (incidences >10%) are hot
flushes, upper respiratory infection, fatigue, diarrhea, pollakiuria,
arthralgia, and injection site pain.
Use in specific populations:
Lactation: A decision should be made to discontinue
breastfeeding or discontinue the LEUPROLIDE ACETATE
INJECTION DEPOT.
Females and Males of Reproductive Potential:
LEUPROLIDE ACETATE INJECTION DEPOT may impair fertility
in males of reproductive potential.
Pediatric Use: The safety and effectiveness of LEUPROLIDE
ACETATE INJECTION DEPOT in pediatric patients have not
been established.
Geriatric Use: Hot flushes occurred with equal frequency in
those ≤ 65 years of age.
To report suspected adverse reactions, contact Cipla at
1-866-604-3268 or the FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
www.ciplaleuprolide.com
DETAILS
NDC 1
69097-0909-50
STRENGTH1
22.5 mg
ROUTE OF ADMINISTRATION1
Intramuscular
SELLING UNIT
1 kit consisting of a LEUPROLIDE ACETATE INJECTION MIXJECT single-dose delivery system
STORAGE1
Store at controlled room temperature at 20º-25ºC (68º-77ºF)
SHELF LIFE2
36 months from date of manufacture
Please see www.ciplaleuprolide.com
or scan the QR code for full Prescribing
Information and Important Safety
Information.
HCPCS Code: J1954
• Sterile and Paper Free (USP 797 Compliant).
• Maintains a 100% sterile barrier* with 3X greater adhesion.
*Tested in Nelson Labs, Salt Lake City, UT
• Helps prevent contamination of drugs and
provides added protection to pharmacists.
• Will not fall off, even in cold storage conditions
(down to -20 degrees centigrade).
• Patented dual-layer indicates true tamper-
evidence, with “OPENED” marking.
VIEW TRAINING VIDEOS HERE
Made in the USA
Syringe Seals
IV Bag Port Seals
Belly Button
Bag Seal
Vial Seals
28mm
20mm
13mm
The Most Innovative Tamper-Evident
Seals Throughout the Pharmacy Today
steri-tamp.com
Visit Our Website to Request Samples